UCB is a global biopharma focused on severe diseases in two therapeutic areas: central nervous system and immunology operations.
The company is listed on the Euronext Brussels Stock Exchange and has its headquarters in Brussels, Belgium. It employs more than 8,500 people in more than 40 countries.
Financial Data
-
31st Dec 19 Source: CRO
- €1.1 million turnover
-
-€0.6 million
profit - 0 employees
-
31st Dec 18 Source: CRO
- €36.9 million turnover
-
€25.8 million
profit - 1 employees
- 11 more years available »
Ranking
By Turnover
(€1.1 million)- 964th in Top Companies
- 96th in Health
- 82nd in Pharma
By Employees
(0)- 1026th in Top Companies
- 94th in Health
- 80th in Pharma
-
- 0
- €1.1 million
Employees
- Steve Turley CEO/Managing Director
Latest News
- 4:36pm Debt-ridden Evergrande resumes work on more than 10 property projects
- 2:15pm Brussels warned not to delay tighter capital rules for EU banks
- 1:01pm Labour Court set to propose 5.6% pay rise for construction workers – report
- Oct 23 Eir planning to sell almost half of Irish fibre network
- Oct 22 Methane leak near Cop26 venue underscores emissions challenge